Loading
Thyroid Cancer Diagnosis and Treatment / Cancer Research and Treatments · Review
Frontiers in Immunology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of the literature on crosstalk between the microbiome and immune microenvironment in thyroid carcinoma, synthesizing mechanistic evidence and associations without performing a systematic meta-analysis or reporting clinical trial outcomes. It identifies dysbiosis and microbial metabolites as putative biomarkers and therapeutic targets, but does not establish causal efficacy or practice-changing interventions for thyroid cancer management.
Narrative review. Patients with thyroid carcinoma (TC), the most common cancer of the endocrine system worldwide.
Gut dysbiosis, bacterial lipopolysaccharides (LPS), and short-chain fatty acids (SCFAs) have bidirectional regulatory effects on thyroid function The intratumor microbiome and microbiome-assisted tumor microenvironment modulate multiple mechanisms of immune suppression and metastatic phenotype The role of local microbiome in modulating treatment responses and interactions with the immune TME of thyroid carcinoma remains unknown
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize this as a synthesis of preclinical and mechanistic literature identifying the microbiome as a potential therapeutic target, not as evidence to guide current practice. Future personalized interventions based on microbiome modulation are proposed but require clinical validation before implementation.
A narrative review synthesizing mechanistic and exploratory literature on microbiome-immune interactions in thyroid cancer, raising questions about therapeutic targets rather than testing defined hypotheses with clinical outcomes.
As stated by the source record.
Clinicians should recognize this as a synthesis of preclinical and mechanistic literature identifying the microbiome as a potential therapeutic target, not as evidence to guide current practice. Future personalized interventions based on microbiome modulation are proposed but require clinical validation before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Thyroid carcinoma (TC) is the most common cancer of the endocrine system worldwide, and its incidence has remained stable over the past forty years. Complex hormonal and environmental factors influence TC progression. The gut microbiome, a pivotal mediator in maintaining host physiology and the development of pathology, serves as a biomarker and therapeutic target in cancer immunotherapy. The microbiome-assisted tumor microenvironment (TME) sustains tumors through the modulation of multiple mechanisms. Immune suppression in the TME induces a metastatic phenotype of tumor cells by modulating signaling pathways, cell differentiation, and the innate immune response. Current research has confirmed that gut dysbiosis, bacterial outer membrane components (such as lipopolysaccharides and LPS), and metabolites (such as short-chain fatty acids and SCFAs) have bidirectional regulatory effects on thyroid function. However, the role of the local microbiome in modulating treatment responses and its interactions with the immune TME of TC remains unknown. The literature was searched in PubMed, Web of Science, and Google Scholar using keywords associated with “microbiome” and “thyroid carcinoma”. Research articles, clinical trials, letters, and meta-analyses were published by January 2026. This narrative review summarizes the role of the intratumor microbiome in tumor progression, interactions with chemotherapy, radiotherapy, and targeted therapies. The associations between the microbiome and the immune TME of cancers, as well as the characteristics of the immune TME and alterations in the gut/intratumor microbiome in patients with TC receiving different therapies, are discussed. Mediating microbiome and metabolites might be potential strategies for optimizing personalized therapeutic interventions against TC. Future research should focus on defining microbial signatures associated with treatment success and developing targeted strategies to improve patient outcomes on the basis of microbiome modulation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.